Dr. Ferrer Biopharma to Showcase Groundbreaking Research in Post-COVID Treatment at ERS Congress 2023
6.9.2023 18:17:00 EEST | Business Wire | Press release
Leading pharmaceutical research and development company Dr. Ferrer Biopharma proudly announces its participation in the highly anticipated European Respiratory Society (ERS) Congress 2023 , scheduled in Milan, Italy, from September 9th to 13th. During the event, the company will present late-breaking findings from two randomized controlled trials that shed light on the potential of intranasal Chlorpheniramine to treat post-COVID-19 long-term symptoms.
The ERS Congress serves as a premier platform in respiratory health, featuring the latest advancements in clinical care, scientific research, education, and technology, where experts and researchers worldwide share insights and discoveries, driving progress in respiratory medicine.
Highlighting a pioneering study, the late-breaking abstract by Dr. Ferrer Biopharma introduces Intranasal Chlorpheniramine Maleate (iCPM) as an innovative therapeutic strategy with promising anti-inflammatory and antiviral properties against COVID-19 and respiratory viruses, specifically addressing long-term symptoms. Investigating the effects of this novel approach, Dr. Ferrer Biopharma's presentation delves into the impact of intranasal Chlorpheniramine on post-COVID-19 symptoms, revealing significant improvements in clinical recovery time and alleviation of symptoms like anosmia, ageusia, and cough, as demonstrated by the two randomized trials ACCROS I, and ACCROS III. The subsequent post-trial follow-up highlights Chlorpheniramine's remarkable reduction of post-COVID symptoms by over 90% compared to a placebo.
"The antiviral and anti-inflammatory effect of iCPM can explain the significant impact in reducing time to clinical recovery in the acute illness," said Dr. Franck Rahaghi , Clinical Professor of Medicine and chairman of Cleveland Clinic Florida pulmonary and critical care department, who leads the study. "iCPM may have better impact in reducing long-COVID symptoms. This reformulated treatment could become a cornerstone intervention in addressing the dreaded issue of long-COVID."
"We are excited to unveil the results of our comprehensive research that explores the impact of intranasal chlorpheniramine on post-COVID-19 long-term symptoms," said Dr. Fernando Valerio, Principal Investigator.
The company's participation underscores its dedication to propelling innovation and achieving excellence in respiratory medicine.
About Dr. Ferrer Biopharma:
Dr. Ferrer Biopharma is a pioneering pharmaceutical research and development company dedicated to advancing intranasal medications for treating cough, colds, flu, and allergies. We use advanced technology to bring to the market high-quality, evidence-based, consumer-focused therapies that originated at the bedside.
For more information, please visit DrFerrerBioPharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906892619/en/
Contact information
Daniel Fernández
Marketing Director
+1-954-225-7694
marketing@pulmonary-institute.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TREASoURcE Final Conference: 14 April 2026, Brussels – Circular Systemic Solutions: From Demos to Deployment31.3.2026 10:32:00 EEST | Press release
The EU-funded TREASoURcE project will present its key results and policy messages at the Final Conference on 14 April 2026 in Brussels, bringing together policymakers, industry representatives, researchers, cities and civil society actors from across Europe. The full-day conference focuses on how circular economy solutions can move from pilot projects to broader deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331360899/en/ Join us in Brussels for the TREASoURcE Final Conference on circular solutions. Over four years, TREASoURcE has developed and tested scalable circular solutions across three value chains: plastics, batteries, and biobased side and waste streams. From demonstrations to deployment: addressing Europe’s scaling challenge The final conference responds to one of the key challenges facing Europe’s circular transition: how to move beyond successful local demonstrations towards wider market uptake and
Thermochemical Energy Storage Leader Redoxblox Rebrands as Tempo31.3.2026 10:00:00 EEST | Press release
Redoxblox, a leader in thermochemical energy storage (TCES) on a mission to electrify the world with technology that shifts the power dynamic, today announced its rebrand to Tempo. The new identity marks the company’s transition from technology development to the commercial scaling of its breakthrough electrified heat platform. The rebrand, developed in partnership with renowned creative agency Red Antler, aligns Tempo’s strategic identity with its unique ability to meet the rigorous demands of heavy industry. The name Tempo is a nod to three core pillars of the company’s value proposition: Temperature leadership, the time-shifting of energy, and the pace of both continuous industrial heat delivery and rapid innovation. “As we move from technical validation toward large-scale commercial rollout, our brand must reflect the scale of the challenge we are solving,” said Pasquale Romano, CEO of Tempo. “Tempo represents our ability to deliver the extreme temperatures industry requires while
STV Group and Post-Quantum Successfully Trial World’s First Quantum-Resilient Drones31.3.2026 10:00:00 EEST | Press release
STV Group a.s., a European defence technology integrator with platforms deployed in Ukraine and allied theatres, and Post-Quantum, the UK cybersecurity company, today announced successful testing of the world’s first quantum-safe drones for active deployment across allied theatres. As allied nations adapt to warfighting defined by autonomous systems and drones, the ability to futureproof secure communications between drones and their operators is of paramount importance. Drone swarms procured today may be stored and deployed in future operations years later. This dynamic requires drones manufactured today incorporate encryption that’s resistant to attack by both classical and quantum computers. The collaboration combines STV’s combat-tested unmanned systems and command-and-control infrastructure with Post-Quantum’s patented post-quantum cryptography and secure radio technologies. The two companies have now successfully trialled the new approach at STV’s weapons testing facility in the
Schneider Electric Joins Thread Group Board of Directors31.3.2026 10:00:00 EEST | Press release
The Thread Group, an industry alliance addressing IoT convergence, security, power, and architecture challenges, today announced that Schneider Electric has joined its Board of Directors. A member of the Thread Group since 2015, Schneider Electric will take a more active role in shaping the future of the Thread wireless networking protocol moving forward. This addition comes at a pivotal time for the organization, with Thread recently surpassing 1000 consumer products, and as we continue to see expansion into commercial markets. Thread 1.4 delivers significant benefits for commercial and industrial applications, including seamless communication, enhanced reliability, and performance in expansive IoT deployments. "The entire Thread Group will benefit from Schneider Electric’s deeper engagement in our efforts," said Vividh Siddha, President of Thread Group. "A dedicated member for more than a decade, their expertise in energy management and building automation is invaluable, especially a
Allshares Acquires Technology Company Amalia to Accelerate Innovation in Ownership and Incentive Management31.3.2026 10:00:00 EEST | Press release
Allshares, a global equity and ownership management platform, today announced the acquisition of Amalia, a France-based company specializing in sales commission and performance management software. The acquisition strengthens Allshares' platform, adding a sophisticated, rules-based engine that expands and enhances its end-to-end ownership offering. Founded in 2020, Amalia was built technology-first. Its software is centered on a powerful rules engine that enables intuitive compensation plan design, giving organizations the flexibility to model incentive structures in a fully self-service environment, unlocking new possibilities for incentive management at scale. Supporting more than 40 organizations, including Nespresso, TheFork, and Rakuten, Amalia provides real-time visibility into performance and incentive data, enabling companies to operate complex compensation programs with greater control and efficiency. “From day one, our focus has been to bring clarity to performance-based comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom